TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

William Sandborn  ¹     Geert R. D'Haens  ²     Bruce E. Sands  ³     Remo Panaccione  ⁴     Siew C. Ng  ⁵     Nervin Lawendy  ⁶     nicole kulisek  ⁶     Xiang Guo  ⁶     Rajiv Mundayat  ⁷     Chinyu Su  ⁷     Julian Panés  ^8    
1 University of California San Diego, La Jolla, United States
² Amsterdam University Medical Centres, Amsterdam, Netherlands
³ Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, United States
⁴ University of Calgary, Calgary, AB, Canada
⁵ Institute of Digestive Disease, Department of Medicine and Therapeutics, Hong Kong, Hong Kong
⁶ Pfizer Inc, Collegeville, PA, United States
⁷ Pfizer Inc, New York, NY, United States
⁸ Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

Topic
IBD

Session
IBD drug efficacy and safety

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)